Elixiron Immunotherapeutics

About:

Elixiron Immunotherapeutics is a company developing therapeutics for cancer, rare, and inflammatory disorders

Website: https://www.elixiron.com/

Top Investors: Taiwania Capital Management Corporation, DCI Partners, Fubon Financial Holdings, Alzheimer's Association, Mega International Commercial Bank

Description:

Elixiron Immunotherapeutics is driven by an international team with a shared vision to produce next-generation immunotherapies. This vision drives our mission to target rare and inflammatory disorders as well as cancer for indications that could substantially benefit from advances in immunotherapy approaches. We employ advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary human antibody domain phage display library and a single human B cell antibody cloning platform to develop innovative therapies. Our two lead pipeline candidates are in phase 1 clinical trials. EI-1071, a small molecule inhibitor of CSF-1R kinase activity, is being explored as a potential therapy for Alzheimer's disease as well as tenosynovial giant cell tumors, and a monoclonal antibody, EI-001 is being developed for the treatment of vitiligo and other immunological disorders.